One of the large-cap pharma stocks engaged in the manufacturing, marketing, and distribution of branded generics and generic pharmaceutical products. The stock has jumped 3.75 percent after the company’s management expects double-digit growth in the next 2-3 years and also improving its net profit margin to 50 to 100 basis points annually over the next 3 years.
Stock Price Movement
In Monday’s trading session, Torrent Pharmaceuticals Limited’s share jumped to an intraday high of 3.75 percent from the previous close of Rs. 3,247.75. The stock opened at Rs. 3,240.05 and is currently trading at Rs. 3,328.30, with a high of Rs. 3,369.55 and a low of Rs. 3,240.05. The market capitalization now stands at approximately Rs. 1,12,639.74 crore.
Company Overview
Torrent Pharmaceuticals Limited was established in 1959 and is headquartered in Ahmedabad. The company is a leading Indian multinational specializing in cardiovascular, CNS, gastrointestinal, and women’s healthcare. With operations in more than 50 countries and robust R&D in Gujarat, it drives innovation and growth.
Management Guidance
Torrent Pharmaceuticals expects its profit margins to improve by 50–100 basis points annually over the next three years, driven by price hikes and better operating efficiencies. The company’s capital expenditure is projected at Rs. 250-300 crores per year.
On debt management, Torrent plans to repay Rs. 500-600 crores in the second half of FY25, targeting a net cash status by FY26. In the US market, profitability is expected within three years, supported by stable revenues and 5-7 new product launches in FY26, which could boost growth by 10-15 percent. The company anticipates overall double-digit growth for the next 2-3 years, showcasing strong future prospects.
Also read….
India Business Highlights
Torrent Pharmaceuticals Limited’s India business revenue is growing 13 percent to Rs. 1,632 crores, surpassing the 8 percent Indian Pharmaceutical Market (IPM) growth. The chronic business grew 14 percent, led by strong performance in cardiac and oral anti-diabetic segments.
The cardiac division, contributing the most, achieved 15 percent growth against market growth of 12 percent. The Consumer Health business expanded its reach to 72,000 outlets, driven by focused campaigns for Shelcal 500 and Tedibar. The field force increased to 6,000, with plans for further expansion.
International Business Highlights
Torrent Pharmaceuticals delivered strong international business performance. In Brazil, revenue grew 17 percent to 174 million Brazil is surpassing market growth with the launch of lisdexamfetamine for ADHD in an 800 million Brazil market and 21 filings pending approval.
In Germany, revenue rose 6 percent to 31 million euros, with new tenders expected to boost sales in FY26. In the US, revenue grew 7 percent to USD 32 million, supported by stable performance, while the Indrad facility received a positive USFDA EIR classification.
Recent quarter results
Torrent Pharmaceuticals Limited’s revenue has increased from Rs. 2,732 crore in Q2 FY24 to Rs. 2,809 crore in Q2 FY25, which has grown by 2.82 percent. The net profit has also grown by 13.54 percent, from Rs. 443 crore in Q2 FY24 to Rs. 503 crore in Q2 FY25.
Written By – Nikhil Naik
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
